Diphtheria and tetanus toxoids combined with pertussis vaccine-acellular

PBAC's latest decision on Diphtheria and tetanus toxoids combined with pertussis vaccine-acellular: Recommended with restriction (2017). Considered for Active immunisation against tetanus, diphtheria and pertussis as a booster in pregnant women during the third trimester of each pregnancy, to reduce the risk of pertussis in newborn infants up to 2 months of age.

Eligible population

Pregnant women in the third trimester of each pregnancy, primarily to reduce the risk of pertussis in newborn infants up to 2 months of age.

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Immunogenicity

Pivotal trial size

2,337 patients

Key trials

Blatter 2009, Southern 2005, Td516 2010, Amirthalingam 2016

Comparator

Boostrix

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated as the analysis compared costs only without differential health benefits being established.

Similar precedents

• Diphtheria, tetanus, acellular pertussis vaccine (dtpa)
  similarity 0.85
• Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (dtap)
  similarity 0.79
• Diphtheria + tetanus + acellular pertussis vaccine
  similarity 0.71
• Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine
  similarity 0.68
• Dtpa-hepb-ipv-hib vaccine
  similarity 0.64
• Recombinant syncytial pre-fusion f protein vaccine (rsvpref)
  similarity 0.60